MYL : Analysis & Opinions

  1. How Bristol-Myers Squibb Makes the World Healthier

    April 10, 2015
    Innovation and acquisition: an in depth look at pharma giant Bristol-Myers Squibb.
  2. 5 Drug Companies Profiting From Generics

    August 4, 2014
    Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better-than-expected earnings last week and raised its ...
  3. Valeant Eyes Bausch & Lomb

    May 28, 2013
    Canadian pharmaceutical company Valeant has made a name for itself through acquisitions. On May 27 it announced that it was ...
  4. A Good Deal For Actavis, But Warner Chilcott Goes A Little Cheap

    May 21, 2013
    Actavis gets a very useful asset, while Warner Chilcott shareholders get a decent exit.
  5. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  6. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  7. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  8. Obama’s Corporate Tax Proposal: Which Companies Will Take A Hit?

    February 24, 2012
    President Obama has proposed corporate tax cuts that will lower corporate income taxes from 35% to 28%, but claims he willl ...
  9. "Dominant" Pattern Inspires 4 Buys

    February 1, 2012
    Reverse head-and-shoulders bottom formations in three stocks and an emerging market ETF are creating worthwhile buying opportunities ...
  10. Teva And Mylan Show Some Value Remains In Generics

    August 4, 2011
    These two generics companies seem to be heading in opposite directions, but the values are similar.
  11. 6 Overbought Stocks To Watch

    April 25, 2011
    Let's take a look at a few stocks that have recently entered overbought territory because these could be candidates for a ...
  12. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  13. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament.
  14. Convertible Securities On The Right Track

    September 11, 2009
    For those who need income but don’t want to miss out on moves in the overall market.
  15. Chico's Tops Companies With Insider Buying

    April 21, 2009
    When a company is trading near its high and has recent insider buying, it's definitely worth a closer look.
  16. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  17. Meet Teva, The Generic Giant

    May 15, 2008
    Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals has all ...
Trading Center